Simulations Plus Clears Key Antitrust Hurdle in Altaris Deal
The HSR waiting period has expired, clearing a major regulatory condition for Altaris's pending acquisition of Simulations Plus.
Simulations Plus, Inc. (Nasdaq: SLP) confirmed Thursday that the mandatory antitrust waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired without a government challenge, removing a critical regulatory obstacle to its pending acquisition by private firm Altaris, LLC. The Research Triangle Park, North Carolina-based company is a global leader in model-informed and AI-accelerated drug development serving the biopharma sector.
The expiration of the HSR waiting period is one of several regulatory conditions the deal must satisfy before closing. HSR review requires companies involved in significant mergers and acquisitions to notify federal antitrust regulators — the Federal Trade Commission and the Department of Justice — and observe a mandatory waiting period before completing a transaction, giving the government time to evaluate potential competitive concerns.
Read more Tim Cook and Howard Lutnick Open Apple Plant in Houston →
The deal's progress through the antitrust process signals that federal regulators did not identify sufficient competitive concerns to warrant further scrutiny or block the transaction. For Simulations Plus shareholders and the broader biopharma software sector, the development marks a meaningful step toward the transaction's completion, though additional closing conditions may still need to be met before the acquisition is finalized.
Simulations Plus provides simulation and modeling software and services widely used by pharmaceutical and biotech companies to accelerate drug discovery and development, a niche that has attracted growing investor interest as AI-driven tools reshape how medicines are brought to market. Altaris is a healthcare-focused private investment firm.
Continue reading at BusinessWire.
